BLISSGVS

Bliss GVS Pharma Share Price

₹161.25 +3.11 (1.97%)

17 Jul, 2025 09:31

SIP TrendupStart SIP in BLISSGVS

Start SIP

Performance

  • Low
  • ₹158
  • High
  • ₹162
  • 52 Week Low
  • ₹106
  • 52 Week High
  • ₹186
  • Open Price₹158
  • Previous Close₹158
  • Volume71,047

Investment Returns

  • Over 1 Month + 9.66%
  • Over 3 Month + 30.87%
  • Over 6 Month 0.04%
  • Over 1 Year + 41.36%
SIP Lightning

Smart Investing Starts Here Start SIP with Bliss GVS Pharma for Steady Growth!

Invest Now

Bliss GVS Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 20.2
  • PEG Ratio
  • 1.7
  • Market Cap Cr
  • 1,701
  • P/B Ratio
  • 1.7
  • Average True Range
  • 6.13
  • EPS
  • 7.99
  • Dividend Yield
  • 0.3
  • MACD Signal
  • 5.37
  • RSI
  • 62.02
  • MFI
  • 75.49

Bliss GVS Pharma Financials

Bliss GVS Pharma Technicals

EMA & SMA

Current Price
₹161.25
+ 3.11 (1.97%)
pointer
  • stock-down_img
  • Bearish Moving Average 0
  • stock-up_img
  • Bullish Moving Average 16
  • 20 Day
  • ₹152.52
  • 50 Day
  • ₹143.85
  • 100 Day
  • ₹138.82
  • 200 Day
  • ₹134.95

Resistance and Support

156.77 Pivot Speed
  • R3 166.53
  • R2 162.82
  • R1 160.48
  • S1 154.43
  • S2 150.72
  • S3 148.38

What's your outlook on Bliss GVS Pharma?

You can only vote once!

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Bliss GVS Pharma manufactures and exports pharmaceutical products, specializing in suppositories, pessaries, and oral medications. With a global presence in over 60 countries, it serves therapeutic segments like anti-malarial, antibiotics, and dermatology through its state-of-the-art facilities.

Bliss Gvs Pharma has an operating revenue of Rs. 809.73 Cr. on a trailing 12-month basis. An annual revenue growth of 6% is not great, Pre-tax margin of 16% is great, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 11% and 11% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around -1% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 43 which is a POOR score indicating inconsistency in earnings, a RS Rating of 83 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 92 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Bliss GVS Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-12 Audited Results & Final Dividend
2025-01-28 Quarterly Results & Others To consider other business matters. per share(50%)Dividend
2024-10-24 Quarterly Results
2024-07-24 Quarterly Results
2024-05-02 Audited Results & Final Dividend
Date Purpose Remarks
2025-07-24 FINAL Rs.0.50 per share(50%)Final Dividend
View More

Bliss GVS Pharma F&O

Bliss GVS Pharma Shareholding Pattern

35.29%
0%
6.55%
13.18%
32.63%
12.35%

About Bliss GVS Pharma

  • NSE Symbol
  • BLISSGVS
  • BSE Symbol
  • 506197
  • Managing Director
  • Mr. Gagan Harsh Sharma
  • ISIN
  • INE416D01022

Similar Stocks to Bliss GVS Pharma

Bliss GVS Pharma FAQs

Bliss GVS Pharma share price is ₹161 As on 17 July, 2025 | 09:17

The Market Cap of Bliss GVS Pharma is ₹1701.1 Cr As on 17 July, 2025 | 09:17

The P/E ratio of Bliss GVS Pharma is 20.2 As on 17 July, 2025 | 09:17

The PB ratio of Bliss GVS Pharma is 1.7 As on 17 July, 2025 | 09:17

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23